Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4805669 | 0.99 | MALT1 (0.53) | MALT1RAB9ANPC1KMT2ATDP1 | |
| SCHEMBL5929386 | 0.85 | MALT1 (0.64) | MALT1RAB9ANPC1KMT2ATDP1 | |
| SCHEMBL14262853 | 0.83 | MALT1 (0.52) | MALT1RAB9ANPC1KMT2ATDP1 | |
| SCHEMBL5929390 | 0.81 | KMT2A (0.57) | MALT1RAB9ANPC1KMT2ATDP1 | |
| SCHEMBL3989887 | 0.81 | L3MBTL1 (0.53) | MALT1RAB9ANPC1KMT2ATDP1 | |
| Hydrochloric Acid SCHEMBL5929353 | 0.80 | KMT2A (0.56) | MALT1RAB9ANPC1KMT2ATDP1 | |
| SCHEMBL5929359 | 0.80 | RAB9A (0.55) | MALT1RAB9ANPC1KMT2ASMN1; SMN2 | |
| SCHEMBL13213711 | 0.80 | SMN1; SMN2 (0.69) | KMT2AMEN1SMN1; SMN2ALDH1A1CYP2C19 | |
| SCHEMBL6104284 | 0.80 | POLB (0.77) | KMT2ATDP1POLBSMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5929348 | 0.79 | RAB9A (0.54) | MALT1RAB9ANPC1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1568683-B1 | Secondary, N-alkylaminated para-phenylenediamines, compositions for dyeing keratinic fibres containing them, processes using this compositions and uses thereof | OREAL (FR) | 2009-05-27 | — | — | EP | claimed |
| US-7338536-B2 | N-alkylamino secondary para-phenylenediamine, composition for dyeing keratin fibers comprising such a para-phenylenediamine, processes using this composition and uses thereof | L'OREAL S. A. (FR) | 2008-03-04 | — | — | US | claimed |
| US-20060026772-A1 | N-alkylamino secondary para-phenylenediamine, composition for dyeing keratin fibers comprising such a para-phenylenediamine, processes using this composition and uses thereof | L'OREAL | 2006-02-09 | — | — | US | claimed |
| EP-1568683-A2 | Secondary, N-alkylaminated para-phenylenediamines, compositions for dyeing keratinic fibres containing them, processes using this compositions and uses thereof | L'OREAL (FR) | 2005-08-31 | — | — | EP | claimed |
| EP-2681221-B1 | TRICYCLIC INHIBITORS OF KINASES | ABBVIE INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-8710065-B2 | Tricyclic inhibitors of kinases | ABBVIE INC. (US) | 2014-04-29 | — | — | US | disclosed |
| EP-2681221-A1 | TRICYCLIC INHIBITORS OF KINASES | AbbVie Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012161812-A1 | TRICYCLIC INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20120220572-A1 | TRICYCLIC INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-08-30 | — | — | US | disclosed |
| EP-1568683-B1 | Secondary, N-alkylaminated para-phenylenediamines, compositions for dyeing keratinic fibres containing them, processes using this compositions and uses thereof | OREAL (FR) | 2009-05-27 | — | — | EP | disclosed |
| US-7338536-B2 | N-alkylamino secondary para-phenylenediamine, composition for dyeing keratin fibers comprising such a para-phenylenediamine, processes using this composition and uses thereof | L'OREAL S. A. (FR) | 2008-03-04 | — | — | US | disclosed |
| US-7338536-B2 | N-alkylamino secondary para-phenylenediamine, composition for dyeing keratin fibers comprising such a para-phenylenediamine, processes using this composition and uses thereof | L'OREAL S. A. (FR) | 2008-03-04 | — | — | US | disclosed |
| US-7338536-B2 | N-alkylamino secondary para-phenylenediamine, composition for dyeing keratin fibers comprising such a para-phenylenediamine, processes using this composition and uses thereof | L'OREAL S. A. (FR) | 2008-03-04 | — | — | US | disclosed |
| EP-1568683-A2 | Secondary, N-alkylaminated para-phenylenediamines, compositions for dyeing keratinic fibres containing them, processes using this compositions and uses thereof | L'OREAL (FR) | 2005-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220572-A1 | TRICYCLIC INHIBITORS OF KINASES | WEE1, WEE2, CDK1 | MALT1 1679/4885RAB9A 2519/4885NPC1 3019/4885 |
| US-20060026772-A1 | N-alkylamino secondary para-phenylenediamine, composition for dyeing keratin fibers comprising such a para-phenylenediamine, processes using this composition and uses thereof | KRT18, CDC73, PRKDC | MALT1 3658/4885RAB9A 4024/4885NPC1 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.